Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. It has a research collaboration with Amsterdam University Medical Center to develop a blood based test that measures naturally occurring antibodies against toxic amyloid ß oligomers. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden.
Frequently asked questions
What sector does Alzinova AB (ALZ) operate in?
Alzinova AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Alzinova AB (ALZ) current stock price?
As of the latest data, Alzinova AB stock price is SEK 1.00, with a previous close of SEK 0.92. Alzinova AB gained SEK 0.08 in the last trading session, representing a 8.68% increase.
What is Alzinova AB (ALZ) current market capitalization?
Alzinova AB market cap is approximately 203.05 million.
What is Alzinova AB (ALZ) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.20, and the forward EPS is -SEK 0.38.
What is Alzinova AB (ALZ) EBITDA?
Alzinova AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -4.93 million.
Does Alzinova AB (ALZ) pay dividends?
No. Alzinova AB does not pay a dividend.
What is Alzinova AB (ALZ) beta (volatility) score?
Alzinova AB has a beta of 1.113, meaning its volatility is roughly in line with the market.
